BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold

  • Tucked in its Q1 earnings release, a voluntary pause for BioCryst Pharmaceuticals Inc's BCRX complement-mediated disease therapy has been upgraded to a partial FDA clinical hold.
  • The update clarified why the company paused trials testing ​​BCX9930 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disorder marked by the destruction of red blood cells and poor bone marrow function. 
  • BioCryst investigates elevated serum creatinine levels, a sign of impaired kidney function.
  • A preliminary investigation has found that the 500 mg dose level, particularly without escalation, is a plausible contributory factor. 
  • BioCryst also disclosed that "subsequent" to its voluntary pause, the FDA slapped on a partial clinical hold. 
  • Separately, "slowly evolving" increases in creatinine levels were identified in roughly 40% of patients who switched to the 500 mg dose in the open-label extension of the proof-of-concept Renew study. 
  • BioCryst now believes that lowering the dose to 400 mg could be used. 
  • The company held $446.8 million in cash and investments but expects operating expenses in 2022 to be as much as $480 million. 
  • Price Action: BCRX shares are down 4.52% at $9.72 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!